ClinicalThought
View More
What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.
How could emerging therapies targeting HER2, HER3, and TROP2 affect management of patients with NSCLC? Here are my thoughts on promising agents and potential clinical implications.
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.